Comparative Pharmacology
Head-to-head clinical analysis: HEPZATO versus NEOSAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPZATO versus NEOSAR.
HEPZATO vs NEOSAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEPZATO (melphalan) is a nitrogen mustard alkylating agent that crosslinks DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
Melphalan 3 mg/kg ideal body weight via hepatic artery infusion over 15-30 minutes followed by hemofiltration, administered once per treatment cycle.
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
None Documented
None Documented
The terminal elimination half-life of melphalan is approximately 1.5 hours following intravenous administration. This short half-life necessitates regional delivery (hepatic arterial infusion) to achieve high local concentrations with limited systemic exposure.
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
HEPZATO (melphalan hydrochloride) for injection is renally eliminated; approximately 20-30% of the administered dose is excreted unchanged in the urine over 24 hours. The major metabolites are hydrolysis products, which are also excreted renally. Biliary/fecal elimination accounts for less than 10% of the dose.
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Category C
Category C
Alkylating Agent
Alkylating Agent